MSH3 and Huntington disease: Moreover, lowering MSH3—via genetic ablation, dose-dependent knockdown, or ASO treatment—significantly suppresses somatic expansion (often without obvious safety liabilities in models), underscoring MSH3 inhibition as a promising therapeutic strategy for HD.